Silence Therapeutics (NASDAQ:SLN) Earns Buy Rating from HC Wainwright

Silence Therapeutics (NASDAQ:SLN)‘s stock had its “buy” rating reaffirmed by stock analysts at HC Wainwright in a report issued on Friday,Benzinga reports. They presently have a $75.00 price objective on the stock.

Several other research firms have also weighed in on SLN. The Goldman Sachs Group cut their target price on shares of Silence Therapeutics from $6.00 to $4.00 and set a “sell” rating for the company in a report on Tuesday, March 4th. William Blair reaffirmed an “outperform” rating on shares of Silence Therapeutics in a report on Tuesday, November 19th. Chardan Capital reaffirmed a “buy” rating and set a $55.00 target price on shares of Silence Therapeutics in a report on Tuesday, December 10th. BMO Capital Markets cut their target price on shares of Silence Therapeutics from $67.00 to $25.00 and set an “outperform” rating for the company in a report on Tuesday, March 4th. Finally, Morgan Stanley cut their target price on shares of Silence Therapeutics from $49.00 to $45.00 and set an “overweight” rating for the company in a report on Wednesday. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $40.67.

Silence Therapeutics Trading Up 2.3 %

SLN opened at $4.85 on Friday. Silence Therapeutics has a 12-month low of $4.06 and a 12-month high of $27.72. The firm has a market capitalization of $145.16 million, a PE ratio of -3.09 and a beta of 1.08. The firm has a 50 day moving average of $5.40 and a two-hundred day moving average of $11.37.

Institutional Investors Weigh In On Silence Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Redmile Group LLC increased its holdings in Silence Therapeutics by 26.3% in the 4th quarter. Redmile Group LLC now owns 2,399,317 shares of the company’s stock worth $16,507,000 after acquiring an additional 500,000 shares in the last quarter. Janus Henderson Group PLC increased its holdings in Silence Therapeutics by 32.8% in the 3rd quarter. Janus Henderson Group PLC now owns 1,087,228 shares of the company’s stock worth $19,798,000 after acquiring an additional 268,250 shares in the last quarter. Nantahala Capital Management LLC boosted its stake in Silence Therapeutics by 424.8% during the 4th quarter. Nantahala Capital Management LLC now owns 1,049,676 shares of the company’s stock worth $7,222,000 after purchasing an additional 849,676 shares during the last quarter. Eventide Asset Management LLC acquired a new stake in Silence Therapeutics during the 3rd quarter worth $11,635,000. Finally, Point72 Asset Management L.P. boosted its stake in Silence Therapeutics by 35.3% during the 4th quarter. Point72 Asset Management L.P. now owns 633,100 shares of the company’s stock worth $4,356,000 after purchasing an additional 165,300 shares during the last quarter. Hedge funds and other institutional investors own 98.73% of the company’s stock.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.